Llwytho...
Receptor for Advanced Glycation Endproduct Modulators: A New Therapeutic Target in Alzheimer’s Disease
INTRODUCTION: Reduction in the deposition of amyloid beta (Aβ) has been the primary target for Alzheimer’s disease (AD) therapeutics recently, but in clinical trials this approach has generally been unsuccessful. A common feature of AD pathology is a complex inflammatory component that could be a ta...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Expert Opin Investig Drugs |
|---|---|
| Prif Awduron: | , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
2015
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5502774/ https://ncbi.nlm.nih.gov/pubmed/25586103 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/13543784.2015.1001490 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|